Skip to main content
TipRanks
Go Ultimate75% OFF

Viking Therapeutics (1VT) Q3 2026 Earnings Report

76 Followers

DE:1VT Q3 2026 EPS Results

Actual EPS
-EUR 1.41
Consensus EPS
-EUR 0.97
Beat/Miss
Missed by -EUR 0.44
One Year Ago EPS
-EUR 0.74

DE:1VT Q3 2026 Revenue Results

Actual Revenue
EUR 0
Expected Revenue
EUR 0
Beat/Miss
Met expectations
YoY Revenue Growth
―

Earnings Announcement Details

Quarter
Q3 2026
Date
10/28/2026
Time
After Close
Conference Call
Wednesday, October 28, 2026
DE:1VT Upcoming Earnings

Viking Therapeutics's next earnings date is estimated for February 10, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:1VT Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Oct 28, 2026|% Change Since:12.58%|
Earnings Call Sentiment|Positive

The call was strongly positive on clinical and operational progress. Viking reported fully enrolled and on-track subcutaneous Phase III studies, initiation of the oral Phase III program, encouraging efficacy and tolerability results from VK2735 maintenance studies, advancement of VK3019, and a substantially strengthened cash position. The main negative factors were sharply higher operating expenses, a substantially wider net loss, ongoing cash usage of around $100 million per quarter, and uncertainty around future maintenance-study and regulatory outcomes. Highlights significantly outweighed lowlights.

Company Guidance

Viking expects the first patients to enter the VANQUISH extension period in early 2027, with the subcutaneous VANQUISH studies assessing once-weekly dosing for 78 weeks; it expects to complete the VK3019 single ascending dose study later this quarter, or by year-end, and plans to initiate a multiple ascending dose study in the first quarter of 2027. The SUNRISE Phase III studies will evaluate oral VK2735 dosed once daily for 68 weeks at 27.5 milligrams, 35 milligrams, 55 milligrams or placebo, with 4-week titration blocks, while Part 2 of the maintenance study will evaluate oral doses ranging from around 17 to 55 with 5 arms, plus 6 subcu arms, 3 every other week and 3 monthly, with results expected in 2027. The company expects a cash usage of average of around $100 million per quarter, with some quarters higher and some lower, SG&A fairly flat in the near term and a pickup later more toward commercialization, which is 2.5 years out from potential launch.

  • VANQUISH Phase III Program Remains on TrackBoth Phase III VANQUISH studies of subcutaneous VK2735—VANQUISH-1 in adults with obesity and VANQUISH-2 in adults with obesity and type 2 diabetes—are fully enrolled and continued to advance according to plan. The studies evaluate weekly doses of 7.5 mg, 12.5 mg and 17.5 mg over 78 weeks, with the first patients expected to enter extension periods in early 2027.
  • SUNRISE Oral Phase III Program InitiatedViking initiated the SUNRISE Phase III registration program for once-daily oral VK2735, consisting of studies in adults with obesity and adults with obesity and type 2 diabetes. The 68-week studies are evaluating 27.5 mg, 35 mg and 55 mg doses versus placebo. The company stated that, if successful and approved, oral VK2735 could become the first approved oral dual GLP-1/GIP agonist.
  • Strong Subcutaneous VK2735 Phase II EfficacyIn the Phase II VENTURE study, weekly subcutaneous VK2735 produced statistically significant mean body-weight reductions of up to 14.7% from baseline after 13 weekly doses, with no signs of plateau. The compound was described as safe and well tolerated, with the majority of treatment-emergent adverse events characterized as mild or moderate.
  • Positive Oral VK2735 Phase II ResultsTop-line results from the Phase II VENTURE oral dosing study showed statistically significant mean body-weight reductions of up to 12.2% from baseline after 13 weeks. The tablet formulation demonstrated encouraging safety and tolerability, with the vast majority of drug-related treatment-emergent adverse events characterized as mild or moderate.
  • Maintenance Study Demonstrated Continued Weight LossDuring the 21-week weekly induction period of the maintenance study, VK2735-treated subjects achieved approximately 16% to approximately 19% weight loss versus approximately 0% for placebo. At week 21, 90% of treated subjects achieved at least 10% weight loss and approximately one-third achieved 20% weight loss. Subjects maintained on 17.5 mg weekly for 33 weeks achieved mean weight loss of approximately 22% from baseline, with no observed plateau.
  • Positive Every-Other-Week and Monthly Maintenance ResultsAfter transitioning from weekly dosing to every-other-week dosing, VK2735-treated subjects retained 83% to 97% of mean weight loss at week 33, compared with 61% among subjects transitioned from 17.5 mg weekly to placebo. For monthly dosing, treated subjects retained 82% to 90% of mean weight loss, also compared with 61% for placebo. Viking stated that dosing was reduced by up to 85% in these cohorts.
  • Maintenance Regimens Showed Favorable TolerabilityDuring the 12-week maintenance phase, treatment-emergent adverse events and overall rates of nausea, vomiting, diarrhea and constipation for both every-other-week and monthly dosing were not meaningfully different from placebo. During induction, gastrointestinal event rates were consistent with the prior VENTURE study despite a faster 2-week titration schedule versus 3 weeks in VENTURE.
  • Part 2 Maintenance Study InitiatedViking initiated Part 2 of the maintenance study to evaluate daily oral dosing, every-other-week subcutaneous dosing, monthly subcutaneous dosing and placebo after an initial 21-week weekly subcutaneous induction period. The oral arms will evaluate doses ranging from around 17 mg to 55 mg, while the study includes three every-other-week and three monthly subcutaneous arms. Results are expected in 2027.
  • VK3019 Amylin Program Advancing Toward Multiple-Dose StudyThe novel amylin and calcitonin receptor dual agonist VK3019 continued in a Phase I single ascending dose study, which Viking expects to complete later in the quarter. The company plans to initiate a multiple ascending dose study in the first quarter of 2027. Preclinical data showed effects on body weight, food intake and metabolism in healthy rats, diet-induced obese mice and obese primates.
  • Substantial Financing and Increased Cash PositionViking closed concurrent upsized common-stock and convertible-note offerings that generated approximately $575 million in gross proceeds and approximately $550 million in net proceeds. Cash, cash equivalents and short-term investments totaled $960 million at September 30, 2026, compared with $706 million at December 31, 2025. Management said the funds substantially increase financial runway and support clinical development, commercial operations and potential launch plans.
  • Commercial and Manufacturing Infrastructure ExpandedViking reported a commercial team that includes an SVP of Commercial, a VP of Market Access, a VP of Medical Affairs, Health Economics and Outcomes Research, and a Director of Medical Science Liaisons. The company also added staff in technical operations, CMC, supply chain, quality and compliance to prepare for commercialization.
  • VK2735 Offers Multiple Formulation and Dosing OptionsManagement identified subcutaneous and oral formulations of the same molecule, along with weekly, every-other-week and monthly dosing options, as potential differentiators. Viking stated that the ability to use the same therapeutic agent for initial weight loss and maintenance may reduce the risk of unexpected adverse events compared with switching between different agents.
  • Clinical Trial Retention and Enrollment Tracking Within ExpectationsManagement stated that the blinded discontinuation rate in VANQUISH is tracking expectations established when the study was designed. Viking was also satisfied with the early SUNRISE enrollment trajectory and said it had no problems identifying additional obesity trial sites.
  • Potential Maintenance Label Supported by Future DataManagement said the VANQUISH extension studies could support potential maintenance language in the product label, while noting that regulatory review issues remain. Viking expects the VANQUISH extension data to be a longer and larger data set than the initial maintenance study and plans to use it for potential regulatory support.

DE:1VT Earnings History

DE:1VT earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 10, 20272026 (Q4)-1.25--1.26――
Oct 28, 20262026 (Q3)-0.97-1.41-0.74-91.36% (-0.67)
Jul 29, 20262026 (Q2)-1.12-1.00-0.53-89.66% (-0.47)
Apr 29, 20262026 (Q1)-0.89-1.25-0.37-234.15% (-0.87)
Feb 11, 20262025 (Q4)-0.81-1.26-0.29-331.25% (-0.96)
Oct 22, 20252025 (Q3)-0.65-0.74-0.2-268.18% (-0.54)
Jul 24, 20252025 (Q2)-0.41-0.53-0.18-190.00% (-0.35)
Apr 23, 20252025 (Q1)-0.30-0.37-0.24-57.69% (-0.14)
Feb 05, 20252024 (Q4)-0.25-0.29-0.23-28.00% (-0.06)
Oct 23, 20242024 (Q3)-0.22-0.20-0.214.35% (+0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed